Merz Therapeutics

Merz Therapeutics is dedicated to improving the lives of patients around the world with its relentless research, development, and culture of innovation. Merz Therapeutics strives to serve unmet patient needs and realize better outcomes.

Stefan Brinkmann

CEO

1 past transactions

Vensica

Corporate Round in 2022
Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica’s device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.